ABL1 and chronic myelogenous leukemia, BCR-ABL1 positive: Dasatinib was approved by the FDA in 2006 for the treatment of resistant, recurrent chronic myelogenous leukemia, based upon potent inhibition of several mutant forms of the BCR-ABL kinase that leads to improved survival.